KOMBIGLYZE – XR 2.5 / 1000 MG 60 TAB

** Kombiglyze™ XR (saxagliptin and metformin HCl extended-release) 2.5 mg/1000 mg 60 Tablets. Once A Day.

** For Oral Use.

** Composition:
Each tablet contains:
Saxagliptin hydrochloride (anhydrous) 2.79 mg equivalent to Saxagliptin 2.5 mg and
Metformin hydrochloride 1000 mg

** Indications and Usage:
Kombiglyze XR is a combination of saxagliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
Limitation of Use:
– Not for treatment of type 1 diabetes or diabetic ketoacidosis
– Has not been studied in patients with a history of pancreatitis.

** Do not crush, cut, or chew tablets. Tablets must be swallowed whole.

** See accompanying package insert for indications and dosing information.

** Store below 30 degrees C.
Keep out of reach of children.

** Manufactured by:
Bristol-Myers Squibb Company
4601 Highway 62 East Mount Vernon, Indiana 47620, USA

Marketed by:
Bristol-Myers Squibb and AstraZeneca

Kombiglyze is a trademark of Bristol-Myers Squibb Company.

Marketing Authorisation Holder is Bristol-Myers Squibb, Princeton, NJ 08453, USA

استيراد : الشركة المتحدة للتوزيع ومستلزمات الصيدليات